Julia Brown, an advisor and former executive with Amylin Pharmaceuticals, is the newest member of the board of directors at Targacept.
Brown, who was named to the Targacept board on Nov. 29, has more than 30 years of experience in the life science sector. She worked for more than 25 years at Eli Lilly. Brown also serves on the boards of three other firms.
Targacept is developing a number of drugs based on neuronal nicotinic receptors.